PT - JOURNAL ARTICLE AU - Wade, Stephen AU - Ngo, Preston AU - He, Yue AU - Caruana, Michael AU - Steinberg, Julia AU - Luo, Qingwei AU - David, Michael AU - McWilliams, Annette AU - Fong, Kwun M AU - Canfell, Karen AU - Weber, Marianne TI - Estimates of the eligible population for Australia’s targeted National Lung Cancer Screening Program, 2025-2030 AID - 10.1101/2024.07.02.24309739 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.02.24309739 4099 - http://medrxiv.org/content/early/2024/07/03/2024.07.02.24309739.short 4100 - http://medrxiv.org/content/early/2024/07/03/2024.07.02.24309739.full AB - Australia’s National Lung Cancer Screening Program will commence in July 2025, targeted at individuals aged 50-70 years with a 30 pack-year smoking history, who either currently smoke or have quit within the last 10 years. We forecasted the number of screening-eligible individuals over the first 5 years of the program using data from the 2019 National Drug Strategy Household Survey, and the 2022 Australian Bureau of Statistics population projections. Multiple imputation integrated with predictive modelling of future or unmeasured smoking characteristics was used to address missing data and simultaneously, to project individuals’ smoking histories to 2030. In 2025, 930,500 (95% prediction interval 852,200-1,019,000) individuals were estimated to be eligible, with the number meeting the criteria declining slightly over the years 2025-2030 in all Australian jurisdictions. Overall, 26-30% of those eligible will have quit smoking, and 70-74% will currently smoke. These estimates can be used in resource planning and as an indicative denominator to track participation rates for the program over time.Competing Interest StatementKaren Canfell is co-primary investigator in an investigator-initiated trial of cervical screening, 'Compass', run by the Australian Centre for Prevention of Cervical Cancer (ACPCC), a government-funded not-for-profit charity. Compass receives infrastructure support from the Australian government; the ACPCC has received equipment and a funding contribution from Roche Molecular Diagnostics, and operational support from the Australian government. Karen Canfell is also co-primary investigator in an investigator-initiated implementation program, Elimination of Cervical Cancer in the Western Pacific (ECCWP), which receives support from the Minderoo Foundation and equipment donations from Cepheid Inc. Karen Canfell also receives support for a range of other Australian and international projects related to cervical cancer control, including support from philanthropic organisations, the World Health Organization, and government agencies, together with contract funding for monitoring the safety of the National Cervical Screening Program. None of these are directly related to the study reported in this article. All other authors have no competing interest.Funding StatementThis work was funded by a Medical Research Future Fund (MRFF) Preventive and Public Health Research Initiative: 2019 Target Health System and Community Organisation Research Grant Opportunity, No. MRF1200535.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This report uses de-identified data from the National Drug Strategy Household Survey, supplied by the Australian Institute of Health and Welfare: https://www.aihw.gov.au/about-our-data/our-data-collections/national-drug-strategy-household-survey/2022-ndshs The Australian Institute of Health and Welfare ethics committee of the Australian Institute of Health and Welfare waived ethical approval for this work. Use of the data were supplied under a Confidentiality Undertaking made in pursuance of section 29 of the Australian Institute of Health and Welfare Act 1987 (AIHW Act) to Dr Stephen Wade at Cancer Council NSW. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript using the National Drug strategy Household Survey available from the AIHW: https://www.aihw.gov.au/about-our-data/accessing-data-through-the-aihw/data-on-request